CAMBRIDGE, Mass., – September 17, 2020 – HiFiBiO Therapeutics is presenting a novel approach for patient stratification demonstrating its proprietary Drug Intelligent Science (DIS™) single-cell platform at the American Association for Cancer Research (AACR) Tumor Heterogeneity Virtual Special Conference taking place today. The company is a pioneer of novel antibody drug discovery and development, leveraging single-cell analytics to treat cancer, autoimmune and infectious disorders. HiFiBiO invites members of the scientific and medical communities to listen to the poster presentation online at the AACR meeting website or, after the AACR meeting has concluded, on the HiFiBiO Therapeutics website.
“This presentation demonstrates the potential of our DIS single-cell platform to identify biomarkers that can predict if patients will respond to treatment,” said Andreas Raue, PhD, Senior Director and Head of Drug Intelligent Science at HiFiBiO Therapeutics. “Given our depth of experience in immune modulation and single-cell science, we believe our DIS platform has the potential to transform how we mine immune biomarkers to identify the best immunotherapies for each and every patient.”
Poster Presentation Details
Title: Single-cell immune profiling identifies signature that predicts PD-L1 blockade outcome
Presenter: Dean Lee, Scientist, Drug Intelligent Science at HiFiBiO Therapeutics
About HiFiBiO Therapeutics
HiFiBiO Therapeutics is transforming the field of immunotherapy by combining proprietary single-cell profiling technologies with advanced data intelligence and deep knowledge of immune system biology. This approach enables the development of novel antibody therapies that are paired with biomarkers to predict patient response. HiFiBiO Therapeutics is working actively to address unmet medical needs around the world through its own innovative pipeline programs and open-innovation partnerships with world-renowned industry and academic researchers. The company’s strong global footprint features cutting-edge laboratories on three continents, in Cambridge, Mass., Paris, Shanghai and Hong Kong. To learn more, please visit www.hifibio.com.
HiFiBiO Therapeutics, the HiFiBiO Therapeutics logo, CelliGO, and DIS are trademarks of HiFiBiO and its affiliates.